455 related articles for article (PubMed ID: 24048792)
1. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
2. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
Lamm W; Kaufmann H; Raderer M; Hoffmann M; Chott A; Zielinski C; Drach J
Haematologica; 2011 Jul; 96(7):1008-14. PubMed ID: 21486866
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Zinzani PL; Khuageva NK; Wang H; Garicochea B; Walewski J; Van Hoof A; Soubeyran P; Caballero D; Buckstein R; Esseltine DL; Theocharous P; Enny C; Zhu E; Elsayed YA; Coiffier B
J Hematol Oncol; 2012 Oct; 5():67. PubMed ID: 23088650
[TBL] [Abstract][Full Text] [Related]
6. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
7. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Houot R; Le Gouill S; Ojeda Uribe M; Mounier C; Courby S; Dartigeas C; Bouabdallah K; Alexis Vigier M; Moles MP; Tournilhac O; Arakelyan N; Rodon P; El Yamani A; Sutton L; Fornecker L; Assouline D; Harousseau JL; Maisonneuve H; Caulet-Maugendre S; Gressin R;
Ann Oncol; 2012 Jun; 23(6):1555-61. PubMed ID: 22012966
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Barr PM; Fu P; Lazarus HM; Horvath N; Gerson SL; Koc ON; Bahlis NJ; Snell MR; Dowlati A; Cooper BW
Br J Haematol; 2009 Oct; 147(1):89-96. PubMed ID: 19656151
[TBL] [Abstract][Full Text] [Related]
9. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
12. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
Chang JE; Peterson C; Choi S; Eickhoff JC; Kim K; Yang DT; Gilbert LA; Rogers ES; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Br J Haematol; 2011 Oct; 155(2):190-7. PubMed ID: 21848883
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A
Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Gerecitano J; Portlock C; Hamlin P; Moskowitz CH; Noy A; Straus D; Schulman P; Dumitrescu O; Sarasohn D; Pappanicholaou J; Iasonos A; Zhang Z; Mo Q; Horanlli E; Rojas CN; Zelenetz AD; O'Connor OA
Clin Cancer Res; 2011 Apr; 17(8):2493-501. PubMed ID: 21346146
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Gerecitano J; Portlock C; Moskowitz C; Hamlin P; Straus D; Zelenetz AD; Zhang Z; Dumitrescu O; Sarasohn D; Lin D; Pappanicholaou J; Cortelli BM; Neylon E; Hamelers R; Wright J; O'Connor OA
Br J Haematol; 2009 Sep; 146(6):652-5. PubMed ID: 19624539
[TBL] [Abstract][Full Text] [Related]
19. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
